INCY: Late-stage pipeline and global expansion drive strong post-Jakafi growth outlook
阅读少于1分钟
Management outlined a post-Jakafi growth strategy centered on a robust late-stage pipeline in hematology, oncology, and immunology, with multiple billion-dollar opportunities. Key assets include 989 for MPNs, Opzelura's global expansion, povorcitinib for HS/PN/vitiligo, and solid tumor programs, all supported by strong execution and business development.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr